>
Vaccibody AS logo

VACC - Vaccibody AS Share Price

NOK71.5 -2.0  -2.7%

Last Trade - 21/04/21

Market Cap £1.80bn
Enterprise Value £1.78bn
Revenue £7.49k
Position in Universe 237th / 1829
Bullish
Bearish
Unlock VACC Revenue
Momentum
Relative Strength (%)
1m -17.2%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -53.8%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.24 0.49 0.13 0.49 1,692 742
-64.2
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020,Vaccibody AS revenues decreased 100% to NOK1K. Net lossincreased from NOK62M to NOK127.9M. Revenues reflect adecrease in demand for the Company's products and servicesdue to unfavorable market conditions. Higher net lossreflects Other Operating Expense increase from NOK53.7M toNOK112.9M (expense), Payroll and Related Expenses increaseof 42% to NOK28.2M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

VACC Revenue Unlock VACC Revenue

Net Income

VACC Net Income Unlock VACC Revenue

Normalised EPS

VACC Normalised EPS Unlock VACC Revenue

PE Ratio Range

VACC PE Ratio Range Unlock VACC Revenue

Dividend Yield Range

VACC Dividend Yield Range Unlock VACC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
VACC EPS Forecasts Unlock VACC Revenue
Profile Summary

Vaccibody AS is a Norway-based vaccine company. It is engaged in the development of vaccines that overcome the shortcomings of current vaccine technologies. The Company's vaccine platform increases the antibody and T-cell responses. The Company focuses on cancer vaccines, partnering the technology within infection and veterinary use. The Company develops of an immuntherapy against HPV-induced malignancies, such as precanceous lesions of cervical cancer. The major shareholders of the Company are BMI, Sarsia Seed and the investors.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated January 13, 2007
No. of Shareholders: 317
No. of Employees: 36
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Oslo Stock Exchange
Shares in Issue 283,627,680
Free Float (0.0%)
Eligible for
ISAs
SIPPs
VACC Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for VACC
Upcoming Events for VACC
Wednesday 12th May, 2021
Q1 2021 Vaccibody AS Earnings Release
Thursday 26th August, 2021
Half Year 2021 Vaccibody AS Earnings Release
Frequently Asked Questions for Vaccibody AS
What is the Vaccibody AS share price?

As of 21/04/21, shares in Vaccibody AS are trading at NOK71.5, giving the company a market capitalisation of £1.80bn. This share price information is delayed by 15 minutes.

How has the Vaccibody AS share price performed this year?

Shares in Vaccibody AS are currently trading at NOK71.5 and the price has moved by -29.9% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Vaccibody AS price has moved by -45.57% over the past year.

What are the analyst and broker recommendations for Vaccibody AS?

There are no analysts currently covering Vaccibody AS.

When will Vaccibody AS next release its financial results?

Vaccibody AS is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Vaccibody AS dividend yield?

Vaccibody AS does not currently pay a dividend.

Does Vaccibody AS pay a dividend?

Vaccibody AS does not currently pay a dividend.

When does Vaccibody AS next pay dividends?

Vaccibody AS does not currently pay a dividend.

How do I buy Vaccibody AS shares?

To buy shares in Vaccibody AS you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Vaccibody AS?

Shares in Vaccibody AS are currently trading at NOK71.5, giving the company a market capitalisation of £1.80bn.

Where are Vaccibody AS shares listed? Where are Vaccibody AS shares listed?

Here are the trading details for Vaccibody AS:

Country of listing: Norway
Exchange: OSL
Ticker Symbol: VACC
What kind of share is Vaccibody AS?

Based on an overall assessment of its quality, value and momentum, Vaccibody AS is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Vaccibody AS share price forecast 2021?

Shares in Vaccibody AS are currently priced at NOK71.5. At that level they are trading at 76.87% discount to the analyst consensus target price of 0.00.

Analysts covering Vaccibody AS currently have a consensus Earnings Per Share (EPS) forecast of 4.13 for the next financial year.

How can I tell whether the Vaccibody AS share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vaccibody AS. Over the past six months, the relative strength of its shares against the market has been 7.34%. At the current price of NOK71.5, shares in Vaccibody AS are trading at 20.94% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Vaccibody AS PE Ratio?

We were not able to find PE ratio data for Vaccibody AS.

Who are the key directors of Vaccibody AS?

Vaccibody AS's management team is headed by:

Tom Pike - CHM
Ole Brekke - CEO
Agnete Fredriksen - EXO
Erlend Skagseth - DRC
Ingrid Alfheim - DRC
Lars Nielsen - CFO
Who are the major shareholders of Vaccibody AS?

Here are the top five shareholders of Vaccibody AS based on the size of their shareholding:

RASMUSSENGRUPPEN AS Corporation
Percentage owned: 8.45% (24.1m shares)
RadForsk Corporation
Percentage owned: 8.42% (24.1m shares)
Andenæsgruppen AS Investment Advisor
Percentage owned: 6.19% (17.7m shares)
AS Tanja Corporation
Percentage owned: 4.01% (11.5m shares)
SKØIEN AS Corporation
Percentage owned: 3.51% (10.0m shares)
Similar to VACC
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.